Country Reports

On the verge of its 100th anniversary, the Republic of Turkey appears to be approaching a decisive moment in the trajectory of its healthcare industry. With a comprehensive social security system covering over 95 percent of the population already in the bag, and after more than a decade of investment on world-class infrastructure, the country…

With outstanding fundamentals, including top-class universities and hospitals, a government cognizant of the benefits that a robust research-based biopharma industry brings, and straightforward business processes, Singapore has long been a hub for life science companies looking to penetrate the vast Asia-Pacific region. This exclusive new report deep dives into Singapore’s key attractions for international investors,…

Switzerland continues to hold its own as a focal point for innovation and discovery in global medical science and ranks very highly on the radar of both Big Pharma and the international biotech community alike. As well as Switzerland’s continuing relevance to the European and global pharma industry, pharma is truly at the core of…

Become a PharmaBoardroom Member for free to access this contentJoin the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password * Remember Me Forgot your password? Don't have a PharmaBoardroom account? Create one

A bastion of equality with high levels of healthcare spending, excellent research and universities, a global commitment to improving health outcomes, and a deeply entrenched digital footprint, Norway is full of potential as a life sciences investment destination. This potential, however, has largely remained untapped until now, as the country has focused on its more…

The inaugural edition of the US Healthcare and Life Sciences Review has collated comments and insights from stakeholders across regulators, health insurers, pharma and biotech companies, as well as patient and industry associations, to provide an incisive snapshot of the US healthcare industry during one of its most defining periods, look at how far the…

This exclusive new report examines how Belgium has been able to establish itself as the ‘Pharma Valley of Europe’, famed for the quality and breadth of its medical research, the scale and complexity of its manufacturing infrastructure, and its multilingual, highly skilled, and industry savvy talent pool. It also looks at the wide variety of…

Somewhat of a bastion of openness, predictability, and stability in a region often mired with turmoil, volatility, and economic nationalism, Morocco is increasingly attracting the attention of international investors across a range of industries. Nowhere is this more apparent than in the life sciences, where companies are taking note of the country’s strong business fundamentals,…

Following a battering by the 2008 global financial crisis and the austerity policies the country was forced to implement, Romania’s economy has rebounded well over the past few years, allowing the oft-overlooked Eastern European country to top the European Union table with enviable economic growth rates of around three to four percent over the past…

Home to a USD 3.38 billion pharma market, one of Central and Eastern Europe’s most high-performing healthcare systems, and one of the region’s leading economies, the Czech Republic’s healthcare and life sciences market is fast closing the gap on its Western European equivalents. A traditionally tightly regulated domestic market is undergoing reform, and a more…

The UAE’s pharma market was predicted to grow to USD four billion in 2020, representing a CAGR of 8.5 percent from 2019. The country sits at the heart of the Middle East which, although only making up two percent of the global pharmaceutical industry, has been growing at a rate of ten percent and is…

In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to its citizens. Year-on-year GDP growth stood at 4.8 percent in 2019, driven on by a burgeoning domestic pharmaceuticals industry which accounted for 7.5 percent of…